: Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogs has been used for over two decades for the treatment of well-differentiated neuroendocrine tumors (NETs), and the publication of the NETTER-1 trials has further strengthened its clinical use. However, many aspects of this treatment are still under discussion. The purpose of this review is to collect and discuss the new available evidence, published in 2021, on the use of 177Lu-Oxodotreotide (DOTATATE) or 90Y-Edotreotide (DOTATOC) in adult patients with NETs focusing on the following hot topics: 1) PRRT use in new clinical settings, broaden its indications; 2) the short- and long-term safety; and 3) the identification of prognostic and predictive factors. The review suggests a possible future increase of PRRT applications, using it in other NETs, as a neoadjuvant treatment, or for rechallenge. Regarding safety, available studies, even those with long follow-up, supported the low rates of adverse events, even though 1.8% of treated patients developed a second malignancy. Finally, there is a lack of prognostic and predictive factors for PRRT, with the exception of the crucial role of nuclear imaging for both patient selection and treatment response estimation.

New Insights in PRRT: Lessons From 2021 / Puliani, Giulia; Chiefari, Alfonsina; Mormando, Marilda; Bianchini, Marta; Lauretta, Rosa; Appetecchia, Marialuisa. - In: FRONTIERS IN ENDOCRINOLOGY. - ISSN 1664-2392. - 13:(2022), p. 861434. [10.3389/fendo.2022.861434]

New Insights in PRRT: Lessons From 2021

Puliani, Giulia;Chiefari, Alfonsina;Bianchini, Marta;Lauretta, Rosa;
2022

Abstract

: Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogs has been used for over two decades for the treatment of well-differentiated neuroendocrine tumors (NETs), and the publication of the NETTER-1 trials has further strengthened its clinical use. However, many aspects of this treatment are still under discussion. The purpose of this review is to collect and discuss the new available evidence, published in 2021, on the use of 177Lu-Oxodotreotide (DOTATATE) or 90Y-Edotreotide (DOTATOC) in adult patients with NETs focusing on the following hot topics: 1) PRRT use in new clinical settings, broaden its indications; 2) the short- and long-term safety; and 3) the identification of prognostic and predictive factors. The review suggests a possible future increase of PRRT applications, using it in other NETs, as a neoadjuvant treatment, or for rechallenge. Regarding safety, available studies, even those with long follow-up, supported the low rates of adverse events, even though 1.8% of treated patients developed a second malignancy. Finally, there is a lack of prognostic and predictive factors for PRRT, with the exception of the crucial role of nuclear imaging for both patient selection and treatment response estimation.
2022
neuroendocrine neoplasms; neuroendocrine tumors; peptide receptor radionuclide therapy; predictive factors; prognostic factors; radioligand therapy; safety
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
New Insights in PRRT: Lessons From 2021 / Puliani, Giulia; Chiefari, Alfonsina; Mormando, Marilda; Bianchini, Marta; Lauretta, Rosa; Appetecchia, Marialuisa. - In: FRONTIERS IN ENDOCRINOLOGY. - ISSN 1664-2392. - 13:(2022), p. 861434. [10.3389/fendo.2022.861434]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1630186
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 9
social impact